LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: Relevance to atheroprotection

Journal of Lipid Research

Volumn 52, Issue 12, 2011, Pages 2304-2313

  Orsoni, Alexina ^a,b   Saheb, Samir ^a   Levels, Johannes H M ^c   Dallinga Thie, Geesje ^c   Atassi, Marielle ^a   Bittar, Randa ^a   Robillard, Paul ^a,b   Bruckert, Eric ^a   Kontush, Anatol ^a,b   Carrié, Alain ^a,b   Chapman, John ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apolipoprotein E; HDL proteome; High density lipoprotein heterogeneity; Low density lipoprotein receptor mutations; Premature atherosclerosis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; ATORVASTATIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PRE BETA HIGH DENSITY LIPOPROTEIN;

ADSORPTION; ADULT; APHERESIS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEART PROTECTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; THERAPY EFFECT;

ADSORPTION; ADULT; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CASE-CONTROL STUDIES; FEMALE; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INFLAMMATION; LIPOPROTEINS, LDL; MALE; PROTEOME; RECEPTORS, LDL; RETROSPECTIVE STUDIES;

EID: 81855206685     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P016816     Document Type: Article

References (52)

1. Goldstein, J. L., H. H. Hobbs, and M. S. Brown. 2001. Familial hypercholesterolemia. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 2863-2913.
2. Gordon, D. J., J. L. Probstfield, R. J. Garrison, J. D. Neaton, W. P. Castelli, J. D. Knoke, D. R. Jacobs, S. Bangdiwala, and H. A. Tyroler. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79: 8-15. (Pubitemid 19043669)
3. The Emerging Risk Factors Collaboration. 2009. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 302: 1993-2000.
4. Chapman, M. J., H. N. Ginsberg, P. Amarenco, F. Andreotti, J. Borén, A. L. Catapano, O. S. Descamps, E. Fisher, P. T. Kovanen, J. A. Kuivenhoven, et al. 2011. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32: 1345-1361.
5. Bellanger, N., A. Orsoni, Z. Julia, N. Fournier, E. Frisdal, E. Duchene, E. Bruckert, A. Carrie, D. Bonnefont-Rousselot, J. Pirault, et al. 2011. Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 31: 1675-1681.
6. Guérin, M., P. J. Dolphin, and M. J. Chapman. 1994. Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler. Thromb. 14: 679-685.
7. Miltiadous, G., M. A. Cariolou, and M. Elisaf. 2002. HDL-cholesterol levels in patients with molecularly defined familial hypercholesterolemia. Ann. Clin. Lab. Sci. 32: 50-54. (Pubitemid 34137433)
8. Schaefer, J. R., D. J. Rader, K. Ikewaki, T. Fairwell, L. A. Zech, M. R. Kindt, J. Davignon, R. E. Gregg, and H. B. Brewer, Jr. 1992. In-vivo metabolism of apolipoprotein AI in a patient with homozygous familial hypercholesterolemia. Arterioscler. Thromb. 12: 843-848.
9. Kajinami, K., H. Mabuchi, J. Koizumi, and R. Takeda. 1992. Serum apolipoproteins in heterozygous familial hypercholesterolemia. Clin. Chim. Acta. 211: 93-99.
10. Hogue, J. C., B. Lamarche, D. Gaudet, A. J. Tremblay, J. P. Despres, J. Bergeron, C. Gagne, and P. Couture. 2007. Association of heterozygous familial hypercholesterolemia with smaller HDL particle size. Atherosclerosis. 190: 429-435. (Pubitemid 46074034)
11. Frénais, R., K. Ouguerram, C. Maugeais, J. S. Marchini, P. Benlian, J. M. Bard, T. Magot, and M. Krempf. 1999. Apolipoprotein AI kinetics in heterozygous familial hypercholesterolemia: a stable isotope study. J. Lipid Res. 40: 1506-1511. (Pubitemid 29379992)
12. Gibson, J. C., R. B. Goldberg, A. Rubinstein, H. N. Ginsberg, W. V. Brown, S. Baker, B. I. Joffe, and H. C. Seftel. 1987. Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia. Atherosclerosis. 7: 401-407. (Pubitemid 17098624)
13. Keidar, S., R. E. Ostlund, and G. Schonfeld. 1990. Apolipoprotein- E-rich HDL in patients with homozygous familial hypercholesterolemia. Atherosclerosis. 84: 155-163. (Pubitemid 20360860)
14. Beisiegel, U., W. Weber, G. Ihrke, J. Herz, and K. K. Stanley. 1989. The LDL receptor related protein, LRP, is an apolipoprotein-Ebinding protein. Nature. 341: 162-164.
15. Kowal, R. C., J. Herz, J. L. Goldstein, V. Esser, and M. S. Brown. 1989. Low-density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein-E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA. 86: 5810-5814. (Pubitemid 19217543)
16. Mahley, R. W., Y. Huang, and K. H. Weisgraber. 2006. Putting cholesterol in its place: apoE and reverse cholesterol transport. J. Clin. Invest. 116: 1226-1229.
17. Rall, S. C., K. H. Weisgraber, T. L. Innerarity, and R. W. Mahley. 1982. Structural basis for receptor-binding heterogeneity of apolipoprotein-E from type-III hyperlipoproteinemic subjects. Proc. Natl. Acad. Sci. USA. 79: 4696-4700.
18. Davidson, W. S., R. A. Silva, S. Chantepie, W. R. Lagor, M. J. Chapman, and A. Kontush. 2009. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 29: 870-876.
19. Kontush, A., S. Chantepie, and M. J. Chapman. 2003. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23: 1881-1888. (Pubitemid 37254879)
20. Kontush, A., and M. J. Chapman. 2006. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58: 342-374. (Pubitemid 44394906)
21. Lewis, G. F., and D. J. Rader. 2005. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96: 1221-1232. (Pubitemid 40962099)
22. Rye, K. A., C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter. 2009. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50 (Suppl) : S195-S200.
23. Fielding, C. J., and P. E. Fielding. 1995. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36: 211-228.
24. Sviridov, D., O. Miyazaki, K. Theodore, A. Hoang, I. Fukamachi, and P. Nestel. 2002. Delineation of the role of pre-beta1-HDL in cholesterol efflux using isolated pre-beta1-HDL. Arterioscler. Thromb. Vasc. Biol. 22: 1482-1488.
25. Thompson, G. R. 2003. LDL-apheresis. Atherosclerosis. 167: 1-13.
26. Thompson, G. R., M. Barbir, D. Davies, P. Dobral, M. Gesinde, M. Livingston, P. Mandry, A. D. Marais, S. Matthews, C. Neuwirth, et al. 2010. Efficacy criteria and cholesterol targets for LDLapheresis. Atherosclerosis. 208: 317-321.
27. Moriarty, M. P. 2009. Low-density lipoprotein apheresis. In Clinical Lipidology: a Companion to Braunwald's Heart Disease. C. M. Ballantyne, editor. Saunders Elsevier, Inc., Philadelphia. 363-375.
28. Franceschini, G., P. Apebe, L. Calabresi, G. Busnach, L. Minetti, V. Vaccarino, and C. R. Sirtori. 1988. Alterations in the HDL system after rapid plasma cholesterol reduction by LDL-apheresis. Metabolism. 37: 752.
29. Parhofer, K. G., H. C. Geiss, and P. Schwandt. 2000. Efficacy of different low-density lipoprotein apheresis methods. Ther. Apher. 4: 382-385.
30. Koizumi, J., A. Inazu, H. Fujita, M. Takeda, Y. Uno, K. Kajinami, H. Mabuchi, and R. Takeda. 1988. Removal of apolipoprotein E-enriched high-density lipoprotein by LDL-apheresis in familial hypercholesterolaemia: a possible activation of the reverse cholesterol transport system. Atherosclerosis. 74: 1.
31. Moriarty, P. M., J. P. Luyendyk, C. A. Gibson, and J. M. Backes. 2010. Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein E4. Am. J. Cardiol. 105: 1585-1587.
32. O'Brien, K. D., K. Lewis, J. W. Fischer, P. Johnson, J-Y. Hwang, E. A. Knopp, M. G. Kinsella, P. H. R. Barrett, A. Chait, and T. N. Wight. 2004. Smooth muscle cell biglycan overexpression results in increased lipoprotein retention on extracellular matrix: implications for the retention of lipoproteins in atherosclerosis. Atherosclerosis. 177: 29.
33. O'Brien, K. D., K. L. Olin, C. E. Alpers, W. Chiu, M. Ferguson, K. Hudkins, T. N. Wight, and A. Chait. 1998. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation. 98: 519-527. (Pubitemid 28371249)
34. Olin, K. L., S. Potter-Perigo, P. H. R. Barrett, T. N. Wight, and A. Chait. 2001. Biglycan, a vascular proteoglycan, binds differently to HDL2 and HDL3: role of apoE. Arterioscler. Thromb. Vasc. Biol. 21: 129-135. (Pubitemid 32061937)
35. Thompson, G. R. 2008. Recommendations for the use of LDLapheresis. Atherosclerosis. 198: 247-255.
36. Chapman, M. J., S. Goldstein, D. Lagrange, and P. M. Laplaud. 1981. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res. 22: 339-358. (Pubitemid 11125137)
37. Guérin, M., E. Bruckert, P. J. Dolphin, G. Turpin, and M. J. Chapman. 1996. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 16: 763-772. (Pubitemid 26179365)
38. Hansel, B., P. Giral, E. Nobecourt, S. Chantepie, E. Bruckert, M. J. Chapman, and A. Kontush. 2004. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab. 89: 4963-4971. (Pubitemid 39391435)
39. Lopes-Virella, M. F., P. Stone, S. Ellis, and J. A. Colwell. 1977. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin. Chem. 23: 882-884. (Pubitemid 8088312)
40. Miyazaki, O., J. Kobayashi, I. Fukamachi, T. Miida, H. Bujo, and Y. Saito. 2000. A new sandwich enzyme immunoassay for measurement of plasma pre-beta1-HDL levels. J. Lipid Res. 41: 2083-2088. (Pubitemid 32039004)
41. Levels, J., B. Bleijlevens, F. Rezaee, J. Aerts, and J. Meijers. 2007. SELDI-TOF mass spectrometry of high-density lipoprotein. Proteome Sci. 5: 15.
42. Geurts, P., M. Fillet, D. de Seny, M. A. Meuwis, M. Malaise, M. P. Merville, and L. Wehenkel. 2005. Proteomic mass spectra classification using decision tree based ensemble methods. Bioinformatics. 21: 3138-3145. (Pubitemid 41418467)
43. Rawlins, M. L., S. L. La'ulu, N. Moon, and W. L. Roberts. 2009. Performance characteristics of an immunoturbidimetric assay for lipoprotein-associated phospholipase A2. Clin. Chim. Acta. 406: 66-70.
44. Gordon, B. R., S. F. Kelsey, D. W. Bilheimer, D. C. Brown, P. C. Dau, A. M. Gotto, D. R. Illingworth, P. H. Jones, S. F. Leitman, J. S. Prihoda, et al. 1992. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am. J. Cardiol. 70: 1010.
45. Otto, C., H. C. Geiss, K. Empen, and K. G. Parhofer. 2004. Longterm reduction of C-reactive protein concentration by regular LDL-apheresis. Atherosclerosis. 174: 151-156. (Pubitemid 38607383)
46. Mahley, R. W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240: 622-630.
47. Gordon, S. M., J. Deng, L. J. Lu, and W. S. Davidson. 2010. Proteomic characterization of human plasma high-density lipoprotein fractionated by gel filtration chromatography. J. Proteome Res. 9: 5239-5249.
48. Silva, R. A., R. Huang, J. Morris, J. Fang, E. O. Gracheva, G. Ren, A. Kontush, W. G. Jerome, K. A. Rye, and W. S. Davidson. 2008. Structure of apolipoprotein AI in spherical high density lipoproteins of different sizes. Proc. Natl. Acad. Sci. USA. 105: 12176-12181.
49. Yancey, P. G., H. Yu, M. F. Linton, and S. Fazio. 2007. A pathway-dependent on apoE, ApoAI, and ABCA1 determines formation of buoyant high-density lipoprotein by macrophage foam cells. Arterioscler. Thromb. Vasc. Biol. 27: 1123-1131. (Pubitemid 46641968)
50. Fielding, P. E., and C. J. Fielding. 2002. Biochemistry in lipids, lipoproteins and membranes. In Biochemistry in Lipids, Lipoproteins and Membranes. D. E. Vance and J. E. Vance, editors. Elsevier, Boston. 527-552.
51. Khera, A. V., M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, et al. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364: 127-135.
52. den Dunnen, J., T., and S. E. Antonarakis. 2000. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum. Mutat. 15: 7-12.